AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium+fluvoxamine
Description: the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluvoxamine + lithium + physical therapy
Description: the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment +fluvoxamine
Description: the investigators recommend behavioral therapy as well as drugs.
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine/SNRIs
Description: Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mirtazapine+ Cognitive behavior treatment
Description: the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
Study NCT03219008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine + SNRIs
Description: the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
Study NCT03219008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mirtazapine + SNRIs + physical therapy
Description: the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
Study NCT03219008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU(treat as usual)
Description: patients in this group would receive therapy strategies according to their symptoms and preference.
Study NCT00405639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
Study NCT00405639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be used for placebo.
Study NCT01396395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
Study NCT01396395 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Treatment
Description: The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
Study NCT01396395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
Study NCT00844116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spirometry
Description: Conventional and telematic spirometry
Study NCT00844116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spirometry
Description: Conventional and telematic spirometry
Study NCT00265330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone oral capsules
Description: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
Study NCT03207906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VBP-926
Description: Topical VBP-926 solution
Study NCT00620360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: acute administration of 4 times 0.3g fructose/kg lean body mass
Study NCT00620360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib: 400mg, oral, every day.
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
Study NCT03207906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VBP-926
Description: Topical VBP-926 solution
Study NCT02457416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut
Description: Treatment with peanut in increasing doses until a maintenance dose
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC = 6, 3-week cycle
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 100 mg/m2, weekly
Study NCT04681911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
Study NCT02064504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder
Study NCT03281824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-P7 (HM2-MMAE)
Description: Antibody-Drug Conjugate
Study NCT01635075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1-mile treadmill walk
Study NCT01635075 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: passive control
Description: 20 min inactivity
Study NCT02064504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder
Study NCT01883050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Self Monitoring Software Application
Description: Computer Software application to track health progress after interventional surgery
Study NCT01189318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Extended Release
Description: Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
Study NCT02449304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial ablation (4th gen)
Description: Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
Study NCT03573531 — intervention group
Intervention type: OTHER
Intervention: Laboratory analysis
Description: Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
Study NCT05011786 — intervention group
Intervention type: PROCEDURE
Intervention: hernia repair/ligation of the hernial sac
Description: the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
Study NCT01960452 — intervention group
Intervention type: BEHAVIORAL
Intervention: Serial awakenings
Description: The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
Study NCT00396097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Study NCT04021537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive nerve stimulation
Description: Electrical stimulation will be provided via a TENS unit.
Study NCT04021537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive nerve stimulation
Description: Electrical stimulation will be provided via a TENS unit.
Study NCT00658138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M ESPE Adper Scotchbond SE
Description: To be used per manufacturer's instructions.
Study NCT00658138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M ESPE Adper Scotchbond 1XT
Description: To be used per manufacturer's instructions.
Study NCT03319082 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Corneal Collagen Cross-linking
Description: Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
Study NCT04131595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 1
Description: 1 x 10\^7 Inf.U MVA-BN-WEV vaccine
Study NCT04131595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 2
Description: 1 x 10\^8 Inf.U MVA-BN-WEV vaccine
Study NCT04131595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 3
Description: 2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
Study NCT04013412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-Calorie Restriction
Description: Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
Study NCT03052114 — intervention group
Intervention type: DEVICE
Intervention: Electrical Impedance Tomography
Description: EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
Study NCT01913106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSV-tk +Valacyclovir in Combination with Brachytherapy
Description: The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein.
Study NCT04153149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.
Study NCT04153149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
Study NCT04153149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Sterile normal saline (0.9% NaCl) will be administered by SC injection.
Study NCT03794375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Study NCT03794375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
Study NCT04312672 — intervention group
Intervention type: BIOLOGICAL
Intervention: AAV5-hRKp.RPGR
Description: Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
Study NCT01853631 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
Description: Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2
Study NCT01739218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Study NCT00631410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + mFOLFOX6
Description: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
Study NCT00631410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + mFOLFOX6
Description: 50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
Study NCT02818985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
Study NCT02818985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
Study NCT02818985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
Study NCT01853631 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Description: The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
Study NCT04035486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Drug: Osimertinib (Oral)~Other Names:~AZD9291
Study NCT04035486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT04035486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT03857230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Primapur)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study NCT03857230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Primapur)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study NCT03857230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Gonal-F)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study NCT03305861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ThuLEP
Description: Thulium laser enucleation of prostate
Study NCT03305861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green LEP
Description: Greenlight laser enucleation of prostate